DNLI FY 2018 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$129M

Gross Profit

$129M100.0% margin

Operating Income

-$46M-35.9% margin

Net Income

-$36M-28.1% margin

EPS (Diluted)

$-0.39

Cash Flow

Operating Cash Flow

$50M

Free Cash Flow

$47M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$662M

Total Liabilities

$115M

Stockholders' Equity

$547M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$129M	$0	—
Gross Profit	$129M	-$3M	+4290.8%
Operating Income	-$46M	-$90M	+48.6%
Net Income	-$36M	-$88M	+58.9%